Circassia Pharmaceuticals Inc has received a multiyear Innovative Technology contract for its Niox Vero asthma management products from Vizient Inc, the largest member-owned healthcare company in the United States.
Circassia’s Niox Vero products are used to assist asthma diagnosis and management, and are indicated in the United States for use in those aged 7 years and older. Niox is based on the discovery that patients with Th2 or type 2 driven airway inflammation, the major underlying cause of asthma, generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of this fractional exhaled nitric oxide (FeNO), Niox enables clinicians to evaluate airway inflammation in patients with underlying asthma, aiding diagnosis and helping guide treatment and reduce exacerbations.
“Circassia is proud to be awarded this prestigious Vizient Innovative Technology contract, which recognizes the important role Niox Vero plays in assisting asthma diagnosis and management,” said Steve Harris, CEO of Circassia. “This new contract will provide Circassia with a simplified route to access Vizient members as potential new customers, helping us expand our number of accounts while offering savings opportunities for Niox users.”